A hidden layer of genetic regulation in prostate cancer may offer researchers a new way to weaken aggressive tumors without directly shutting down the genes that drive them. In a study published in the Journal of Experimental & Clinical Cancer Research, scientists mapped how prostate cancer cells process the tail end of the messenger RNA produced by NFYA, a gene that encodes the regulatory subunit NF-YA of the cancer-promoting transcription factor NF-Y. Their findings reveal that tumors frequently switch to shortened versions of NFYA’s three-prime untranslated region, or 3′UTR, producing more NF-YA protein and supporting faster growth, invasion and disease progression. Reversing that RNA-processing decision with gene editing or antisense oligonucleotides suppressed aggressive behavior in cells and reduced tumor growth in animal models. The work points to alternative polyadenylation, a form of RNA processing often overlooked in cancer research, as a potentially targetable vulnerability in prostate cancer.
The discovery centers on what happens after a gene has been transcribed. A newly made messenger RNA contains a protein-coding sequence as well as untranslated regions that help determine how long the molecule survives, where it travels inside the cell and how efficiently it is converted into protein. At the molecule’s three-prime end, cellular machinery cuts the RNA at a selected site and adds a tail of adenine nucleotides, known as a poly(A) tail. This process, called cleavage and polyadenylation, can occur at more than one location. When a cell chooses an upstream polyadenylation signal, the resulting messenger RNA has a shorter 3′UTR; when it uses a downstream signal, the 3′UTR is longer. These alternative transcripts encode the same protein, but their regulatory behavior can be dramatically different. Shortening may remove binding sites for regulatory proteins and other factors that normally restrain gene expression, allowing cancer cells to amplify oncogenic programs without changing the protein-coding DNA itself.
The research team, led by investigators at the University of Milan and collaborating institutions in Italy, Switzerland and the United Kingdom, combined several kinds of sequencing data to reconstruct the NFYA 3′UTR landscape. They examined bulk RNA sequencing, single-cell RNA sequencing and specialized three-prime-end sequencing from prostate cancer cell lines and patient-derived material. This approach identified four functional NFYA 3′UTR isoforms, each terminating at a different polyadenylation site, although one was predominantly used across the cell lines and tissues examined. By measuring the relative use of proximal and distal polyadenylation sites, the researchers could determine whether cancer cells favored shortened or lengthened transcripts. The analysis showed a broad shift toward NFYA 3′UTR shortening in prostate cancer, rather than an isolated change in a small subgroup of tumors. The pattern was associated with higher tumor grade and metastatic disease, suggesting that RNA-end selection tracks with clinically aggressive biology.
The consequences of this shortening were substantial. Tumor samples and prostate cancer models using shorter NFYA transcripts contained more NF-YA protein, while cells with longer 3′UTRs produced less. NF-Y is a transcription factor complex that binds specific DNA elements and regulates genes involved in cell-cycle control, proliferation and other growth-related processes. NF-YA acts as a regulatory component that helps determine which genes the complex can control, so changing its abundance can reshape a large downstream transcriptional network. The investigators found that the short NFYA 3′UTR was linked to increased proliferation and other traits associated with aggressive disease. In this model, cancer progression was not driven simply by producing more NFYA messenger RNA. Instead, the tumor appeared to gain an advantage by selecting an RNA architecture that made the message more effective at generating protein.
The team also investigated how the long 3′UTR reduced NF-YA output. A longer untranslated region can contain additional docking sites for microRNAs, RNA-binding proteins and cellular transport machinery, but the experiments did not support increased microRNA-mediated repression as the main explanation. Instead, lengthening the NFYA 3′UTR reduced messenger RNA stability, impaired translation and increased retention of the transcript inside the nucleus. Messenger RNA stability determines how long a transcript remains available before degradation, while translation is the process by which ribosomes read the coding sequence and build a protein. Nuclear retention creates another bottleneck: even a transcript that has been produced may be less useful if it cannot efficiently reach the cytoplasm, where most translation occurs. Together, these effects sharply reduced the amount of NF-YA protein without eliminating the NFYA gene.
The RNA pattern also changed with the state of the cancer cell. When prostate cancer cells entered quiescence, a relatively inactive state in which proliferation pauses, they shifted toward longer NFYA 3′UTRs. A similar lengthening occurred after treatment with enzalutamide, an androgen-receptor inhibitor used in prostate cancer therapy. The observation connects NFYA RNA processing to both cellular dormancy and drug response. Prostate tumors often adapt to androgen-deprivation strategies, and treatment-resistant disease can eventually progress despite continued therapy. The study does not establish that NFYA 3′UTR lengthening explains enzalutamide’s clinical effects or that manipulating the RNA switch will overcome resistance in patients. It does, however, suggest that the choice of polyadenylation site is dynamic rather than permanently fixed and may reflect the balance between a proliferating, treatment-adapted state and a more restrained cellular condition.
To test whether the RNA-processing switch was merely associated with malignancy or could be manipulated therapeutically, the researchers used two different strategies. In one, CRISPR/Cas9-mediated deletion removed a polyadenylation signal, forcing cells away from the site that generates the shorter transcript and toward production of longer NFYA 3′UTRs. In the other, antisense oligonucleotides were designed to bind and mask polyadenylation signals. These short synthetic nucleic-acid molecules can be engineered to recognize a chosen RNA sequence and physically obstruct the proteins that assemble at a polyadenylation site. Redirecting cleavage in this way offers a potentially gene-specific intervention: rather than degrading every NFYA transcript or blocking NF-YA protein after it is made, the treatment changes which version of the transcript the cell produces. In cultured prostate cancer cells, both approaches lowered NF-YA protein and reduced phenotypes associated with tumor aggressiveness, including enhanced growth.
The strongest test came in vivo, where enforced NFYA 3′UTR lengthening also suppressed aggressive tumor traits and reduced tumor progression in experimental models. The results provide proof of concept, not a ready-made treatment. Antisense drugs must reach the relevant tumor cells, remain stable in the body, enter the correct cellular compartment and avoid unintended effects on other RNAs. Prostate tumors are biologically diverse, and the balance of polyadenylation signals and RNA-binding proteins may differ between patients, treatment histories and metastatic sites. Future studies will need to establish how reliably NFYA 3′UTR patterns predict outcome, whether they can be measured in clinical samples such as biopsies or circulating tumor material, and whether antisense-mediated remodeling is safe and durable in more representative models. Even so, the study expands the therapeutic map of cancer genetics. It shows that an oncogenic protein can be controlled not only by mutations, transcription or protein degradation, but also by the precise way its messenger RNA is finished. For prostate cancer, that overlooked decision at the end of an RNA molecule could become an important new target for precision therapy.
